BusinessRadioMedix and AREVA Med announce initiation of Phase 1 clinical trial of AlphaMedix(TM), a Targeted Alpha Therapy for patients with neuroendocrine tumorsBy Nasdaq OMXJan 10, 2018, 10:00 AM UTC
BusinessRadioMedix Inc. and AREVA Med Announce Completion of the Exploratory Clinical Trial of 203Pb-AR-RMX in patients expressing somatostatin receptor positive neuroendocrine tumorsBy Nasdaq OMXJun 22, 2017, 8:00 PM UTC
BusinessFirst U.S. Multi-center Investigational Clinical Trial of 177 Lu PSMA-617 Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer Receives FDA ClearanceBy Nasdaq OMXFeb 6, 2017, 11:00 AM UTC
BusinessRadioMedix and AREVA Med – SBIR NCI Contract Grant awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212By Nasdaq OMXNov 1, 2016, 5:00 AM UTC
BusinessRadioMedix Inc. successfully completed the Phase I/ II clinical studies for AminoMedix ™ used for radiation kidney protection during Peptide-Receptor Radionuclide Therapy (PRRT)By Nasdaq OMXOct 20, 2016, 6:30 AM UTC
